RT Journal Article
SR Electronic
T1 A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.21.20177238
DO 10.1101/2020.08.21.20177238
A1 Heyckendorf, Jan
A1 Marwitz, Sebastian
A1 Reimann, Maja
A1 Avsar, Korkut
A1 DiNardo, Andrew
A1 Günther, Gunar
A1 Hoelscher, Michael
A1 Ibraim, Elmira
A1 Kalsdorf, Barbara
A1 Kaufmann, Stefan H.E.
A1 Kontsevaya, Irina
A1 Leth, Frank van
A1 Mandalakas, Anna Maria
A1 Maurer, Florian
A1 Müller, Marius
A1 Nitschkowski, Dörte
A1 Olaru, Ioana D.
A1 Popa, Cristina
A1 Rachow, Andrea
A1 Rolling, Thierry
A1 Rybniker, Jan
A1 Salzer, Helmut J. F.
A1 Sanchez-Carballo, Patricia
A1 Schuhmann, Maren
A1 Schaub, Dagmar
A1 Spinu, Victor
A1 Suárez, Isabelle
A1 Terhalle, Elena
A1 Unnewehr, Markus
A1 Weiner, January
A1 Goldmann, Torsten
A1 Lange, Christoph
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.21.20177238.abstract
AB Emerging multidrug-resistant tuberculosis is a major global health challenge. The World Health Organization currently recommends treatment durations of 9–18 months or more for patients with multidrug-resistant tuberculosis. We identified and validated a host-RNA signature to serve as a biomarker for individualized therapy durations for patients with multidrug-resistant tuberculosis. Adult patients with pulmonary tuberculosis were prospectively enrolled into 5 independent cohorts in Germany and Romania. Clinical and microbiological data, and whole-blood for RNA transcriptomic analysis were collected at pre-defined timepoints throughout therapy. Treatment outcomes were ascertained one year after end-of-therapy. A whole-blood RNA therapy end model was developed in a multi-step process involving a machine-learning algorithm to identify hypothetical individual end-of-treatment timepoints. Fifty patients with drug-susceptible tuberculosis and 30 patients with multidrug-resistant tuberculosis were recruited in the German identification cohorts (DS- and MDR-GIC), 28 patients with drug-susceptible tuberculosis and 32 patients with multidrug-resistant tuberculosis in the German validation cohorts (DS- and MDR-GVC), and 52 patients with multidrug-resistant tuberculosis in the Romanian validation cohort (MDR-RVC). A 22-gene RNA model that defined cure-associated end-of-therapy timepoints was derived from the DS- and MDR-GIC data. The model accurately predicted clinical outcomes for patients in the DS-GVC (AUC=0.937 [95%CI:0.899–0.976]) and suggested that cure may be achieved with shorter treatment durations for tuberculosis patients in the MDR-GIC (mean reduction 218.0 days, 34.2%, p<0.001), the MDR-GVC (mean reduction 211.0 days, 32.9%, p<0.001), and the MDR-RVC (mean reduction of 161.0 days, 23.4%, p=0.001). Biomarker-guided management may substantially shorten the duration of therapy for many patients with multidrug-resistant tuberculosis.One Sentence Summary We identified and validated a transcriptome model based on a 22-gene signature to predict individual treatment durations for patients with multidrug-resistant tuberculosis.Competing Interest StatementThe 22-gene model has been patented (EP20158652.6)Clinical TrialNCT02597621Funding StatementSupport by the German Center for Infection Research (DZIF) and the German Center for Lung Research (DZL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approval was granted by the Ethics Committee of the University of Luebeck, Germany (AZ 12-233), which was then approved by the corresponding local Ethic Committees of all participating centers in Germany, and by the Ethics Committee of the Marius Nasta Institute (3181/25.03.2015; Bucharest, Romania).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMicroarray data have been deposited at Gene Expression Omnibus database (GSE147690, GSE147689, GSE147691)